Sign in
CompletedPhase 3

Adjunctive Methylene Blue in Septic Shock

Key facts

Who runs it
Dr. Shannon M. Fernando
Where
Canada2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
50 people enrolled
Started
2 Jun 2025
Ended
6 Mar 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Methylene Blue
  • Usual Care
Record updated
19 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Adult patients (≥ 18 years of age) admitted to the ICU
  • Diagnosed with septic shock (as per the Sepsis-3 Criteria): Suspected infection (i.e. initiation of antimicrobial therapy), coupled with initiation of vasopressor therapy to target a mean arterial pressure (MAP) > 65 mmHg (or as prescribed by the treating clinician), after adequate fluid resuscitation (as per treating clinician)
  • Minimal norepinephrine dose of 0.1 mcg/kg/min for a minimum of 2 hours at the time of enrollment (i.e., the time of randomization)

Who cannot take part

  • Pregnancy **Women of childbearing age (<50 years) should have a urine or beta hCG performed prior to enrolment
  • Concurrent hemorrhagic, obstructive, or hypovolemic shock
  • Known recent intake of selective serotonin re-uptake inhibitors (21 days for norfluoxetine, and 14 days for any other SSRI)
  • Currently receiving linezolid
  • Known Allergy to methylene blue, phenothiazines, or food dyes
  • Known Personal or familial history of glucose-6-phophate dehydrogenase deficiency
  • > 48 hours since initiation of norepinephrine
  • > 48 hours since admission to ICU
  • Anticipation of discontinuation of vasopressors in < 24 hours
  • Plan for withdrawal of life support
  • Major burn injury (>10% total body surface area)

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Adjunctive Methylene BLUe in Septic SHock (BLUSH) is a single centre concealed-allocation parallel-group open-label randomized controlled pilot trial to ascertain the feasibility of a trial evaluating the efficacy and safety of adjunctive methylene blue infusion compared to usual care on outcomes of adult patients admitted to the intensive care unit with septic shock.

The 2 groups in the trial

  • Methylene BlueTreatment being tested

    Methylene Blue infusion: 0.5 mg/kg/hr for 6 hours daily (up to 3 days total).

  • Usual CareExisting treatment, for comparison

    Usual guideline-directed care for adult septic shock.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Adjunctive Methylene BLUe in Septic SHock: a Pilot Randomized Controlled Trial
Record updated
19 March 2026